Alembic Pharmaceuticals Profit up by 78% to Rs. 632 Crores for FY24

365Telugu.com online news, Mumbai,May 9^th, 2024: Alembic Pharmaceuticals Limited reported its consolidated financial results for thefour quarter and yearended 31^stMarch, 2024.

Financial Highlights

For the Quarter

• Net Sales increased8% to Rs.1517 Crores.
• Net Profit up17% to Rs.178Crores
• EBITDA up 29% toRs. 263 Crores.

For the Year

• Net Sales grew 10% to Rs.6229 Crores.
• Net Profit up 80% to Rs.616 Crores
• EBITDA up 41% to Rs. 961 Crores.

Mr. Shaunak Amin, MD, Alembic Pharmaceuticals Limited said “India Branded Business continues to work on improving the execution ability both in quality & scale. The Specialty and Animal health segment witnessed robust growth.

The outlook for the US business appears better, with the commercialization of new facilities and launches set to scale up along with continued progress in achieving cost improvements. The Ex-US generics and the API business maintained a steady continuous growth.”

Operational Highlights

India Branded Business

• India Branded Business grew 3% to Rs. 503 crores for the quarter and grew 7% for the year to Rs. 2,200 cr.
• Witnessed healthy growths in Gynecology, Gastrointestinal, Anti Diabetic and   Ophthalmology therapies as compared to market growth for the quarter and year.
• Relative degree of performance continues to be in line with market for Antibiotic and Respiratory segments despite high base of previous year.
• Animal Health business grew 34% for the quarter and 27% for the year. Basket of strong brands continue to drive outperformance.

International Business

• US Genericsgrew 19% toRs. 423 Crores for the quarter.
• 7 Launches in the US market in Q4
• Ex-US International Formulations grew 5% to Rs. 262 Crores for the quarter.
• 197 Cumulative ANDA approvals.

API Business

• API business grew 5% toRs.330 Crores for the quarter.

The summary of Total Revenue is as under:    (Rs in Crores)

ఇది కూడా చదవండి: అక్షయ తృతీయరోజు పూజలు, షాపింగ్ చేయడానికి ముహూర్తం..